Hinweise zu Qualitätskriterien von Zeitschriften
Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016
CC Licencences
Metriken für Publikationen
Startseite
Login
English
Neuer EVA Antrag
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
HGF Fortschrittsbericht
OA Publikationen
Neue Publikation eintragen
Neue Publikation holen aus...
Fehlende Publikation melden
Ansprechpartner
Hilfe
Bibliometrische Indikatoren
Text
Endnote (RIS)
BibTeX
Verlagsversion
DOI
PMC
 |
Open Access Gold |
|
möglich sobald bei der ZB eingereicht worden ist.
First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: A pilot study.
EJNMMI Res. 13:78 (2023)
Background: Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with 177Lu-labeled 6A10-Fab fragments targeting tumor-associated carbonic anhydrase XII and injected into the resection cavity offers a novel and promising strategy for improved tumor control. Methods: Three glioblastoma patients underwent tumor resection followed by standard radio- and chemotherapy. These patients with stable disease following completion of standard therapy underwent iRIT on compassionate grounds. After surgical implantation of a subcutaneous injection reservoir with a catheter into the resection cavity, a leakage test with [99mTc]Tc-DTPA was performed to rule out leakage into other cerebral compartments. IRIT comprised three consecutive applications over three months for each patient, with 25%, 50%, 25% of the total activity injected. A dosimetry protocol was included with blood sampling and SPECT/CT of the abdomen to calculate doses for the bone marrow and kidneys as potential organs at risk. Results: All three patients presented without relevant leakage after application of [99mTc]Tc-DTPA. Two patients underwent three full cycles of iRIT (592 MBq and 1228 MBq total activity). One patient showed histologically proven tumor progression after the second cycle (526 MBq total activity). No relevant therapy-associated toxicities or adverse events were observed. Dosimetry did not reveal absorbed doses above upper dose limits for organs at risk. Conclusions: In first individual cases, iRIT with [177Lu]Lu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.
Impact Factor
Scopus SNIP
Altmetric
3.200
0.000
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Carbonic Anhydrase Xii ; Glioblastoma ; Immunoglobulin Fab Fragments ; Lutetium-177 ; Radioimmunotherapy; Monoclonal-antibody 81c6; Newly-diagnosed Patients; Malignant Gliomas; Resection Cavity; Phase-ii; Dosimetry; Fab
Sprache
englisch
Veröffentlichungsjahr
2023
HGF-Berichtsjahr
2023
ISSN (print) / ISBN
2191-219X
e-ISSN
2191-219X
Zeitschrift
EJNMMI Research
Quellenangaben
Band: 13,
Heft: 1,
Artikelnummer: 78
Verlag
Springer
Verlagsort
One New York Plaza, Suite 4600, New York, Ny, United States
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Structural Biology (STB)
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-503010-001
Förderungen
Helmholtz-Gemeinschaft
Bundesministerium für Bildung und Forschung
Bundesministerium für Bildung und Forschung
WOS ID
001061437600001
Scopus ID
85169707777
PubMed ID
37665396
Erfassungsdatum
2023-10-18